(Unaudited data)

Development of business in the third quarter (variation at current exchange rates)














In thousands of euros1st quarter2nd quarter3rd quarter
20212020Var.20212020Var.20212020Var.
France51,51872,820-29.3%53,41253,503-0.2%58,02166,390-12.6%
Europe (excluding France)20,03937,581-46.7%22,19416,904+31.3%32,22625,625+25.8%
North America17,65740,272-56.2%17,72321,094-16.0%23,31421,534+8.3%
Other countries1,9585,960-67.2%5,4305,500-1.3%4,1933,018+38.9%
Group total91,172156,633-41.8%98,75997,000+1.8%117,754116,568+1.0%

 

In thousands of euros1st quarter2nd quarter3rd quarter
20212020Var.20212020Var.20212020Var.
Non-proprietary Homeopathic Medicines46,35261,722-24.9%47,64248,334-1.4%45,84050,573-9.4%
OTC Specialties44,57194,619-52.9%50,61748,298+4.8%71,36265,746+8.5%
Other249292-14.8%500368+36.0%552248+122.5%
Group total91,172156,633-41.8%98,75997,000+1.8%117,754116,568+1.0%

Following the sharp decline recorded in the first quarter, revenues in the third quarter continued the trend observed in the second quarter with an increase of 1%.

Sales of non-proprietary medicines continued to decline in France, following the delisting of homeopathic medicines on January 1, 2021.

Specialities continued to grow. The reduction in winter specialities was offset by sales of new products and other specialities, in particular in the United States, Russia, Romania and Bulgaria.

Cumulative activity as of the end of september 2021

In thousands of euros20212020Variation at current
exchange rates		Variation at constant
exchange rates
France162,951192,713-15.4%-15.4%
Europe (excluding France)74,46080,109-7.1%-5.5%
North America58,69482,899-29.2%-25.3%
Other countries11,58114,479-20.0%-16.4%
Group total307,685370,200-16.9%-15.5%

 

In thousands of euros20212020Variation at current
exchange rates		Variation at constant
exchange rates
Non-proprietary Homeopathic Medicines139,834160,628-12.9%-12.3%
OTC Specialties166,550208,663-20.2%-18.3%
Other1,301908+43.3%+44.0%
Group total307,685370,200-16.9%-15.5%

Total sales were down 16.9% over the period ending September 30, impacted by the sharp decline in the first quarter due to the delisting of homeopathic medicines in France, the global pandemic and the absence of winter illnesses.

Thanks to our innovation strategy, sales of new products continued to grow and amounted to around €27 million.

Outlook

We expect to see a further decline in sales of non-proprietary medicines in the fourth quarter versus 2020, following the delisting of homeopathic medicines in France.

Specialty sales will continue to benefit from further growth in new product sales, in particular thanks to the launch of a new range of dermo-cosmetics with organically grown Calendula in September in France, Italy, Spain, Belgium and China, as well as the distribution of Canéphron® in France from October, a traditional herbal medicine developed in partnership with German lab BIONORICA.

We still expect to see a significant decline in revenues over the year.

Full-year operating income will benefit from the comparison effect of the reorganization in France provisioned in 2020, as well as initial savings generated by the reorganization and continued savings on operating expenses.

It will also be boosted by the positive contribution of new product sales.

Although down compared to 2020, we expect to post positive full-year operating income.

We continue to put all our energy and determination into the promotion of Homeopathy in France and around the world.

Laboratoires BOIRON

Our next update:
January 20, 2022: at market close, publication of the sales revenue for the year 2021.
Person responsible for financial information: Valérie Lorentz-Poinsot
Contact for financial information: Fabrice Rey
Investor relations: +33 (0) 4.37.41.84.01 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com


This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: nGduaJ2aZ2qVl5yeaclnZ2aZm5iVl2LIbGWXm5ZpapmXnW9llGmWa5qYZnBim2Zm
- Check this key: https://www.security-master-key.com.

Regulated information:
Quarterly financial reporting:
- Third quarter financial report

Full and original press release in PDF: https://www.actusnews.com/news/71610-boi-211021-activity-q3-2021-gb.pdf

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free


© 2021 ActusNews